Doxazosin resulted in a ‘latent’ induction of TGF-β1 mRNA expression that was subsequent to a moderate increase in the active TGF-β1 levels by prostate cancer cells PC-3 (after 24 h of treatment). This evidence concerns the gene TGFB1 and prostate cancer.